Regulation of zebrafish melanocyte development by ligand-dependent BMP signaling by Gramann, Alec et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2019-12-23 
Regulation of zebrafish melanocyte development by ligand-
dependent BMP signaling 
Alec Gramann 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cancer Biology Commons, Cells Commons, Cellular and Molecular Physiology Commons, 
Developmental Biology Commons, and the Embryonic Structures Commons 
Repository Citation 
Gramann A, Venkatesan AM, Guerin M, Ceol CJ. (2019). Regulation of zebrafish melanocyte development 
by ligand-dependent BMP signaling. Open Access Articles. https://doi.org/10.7554/eLife.50047. 
Retrieved from https://escholarship.umassmed.edu/oapubs/4090 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
1 
REGULATION OF ZEBRAFISH MELANOCYTE DEVELOPMENT BY LIGAND-1 
DEPENDENT BMP SIGNALING 2 
 3 
Alec K. Gramann1, Arvind M. Venkatesan1+, Melissa Guerin1, Craig J. Ceol1* 4 
1. Program in Molecular Medicine and Department of Molecular, Cell, and Cancer 5 
Biology, University of Massachusetts Medical School, 368 Plantation St, 6 
Worcester, MA 01605, USA 7 
+   Present address: Syngene International Ltd., Biocon Park, SEZ, Bommasandra 8 
Jigani Link Road, Phase-IV, Bommasandra Industrial Area, Bangaluru, 9 
Karnataka 560099, India 10 
 11 
*Correspondence: craig.ceol@umassmed.edu 12 
 13 
Abstract 14 
Preventing terminal differentiation is important in the development and progression of 15 
many cancers including melanoma. Recent identification of the BMP ligand GDF6 as a 16 
novel melanoma oncogene showed GDF6-activated BMP signaling suppresses 17 
differentiation of melanoma cells. Previous studies have identified roles for GDF6 18 
orthologs during early embryonic and neural crest development, but have not identified 19 
direct regulation of melanocyte development by GDF6. Here, we investigate the BMP 20 
ligand gdf6a, a zebrafish ortholog of human GDF6, during the development of 21 
melanocytes from the neural crest. We establish that the loss of gdf6a or inhibition of 22 
BMP signaling during neural crest development disrupts normal pigment cell 23 
development, leading to an increase in the number of melanocytes and a corresponding 24 
decrease in iridophores, another neural crest-derived pigment cell type in zebrafish. 25 
This shift occurs as pigment cells arise from the neural crest and depends on mitfa, an 26 
ortholog of MITF, a key regulator of melanocyte development that is also targeted by 27 
oncogenic BMP signaling. Together, these results indicate that the oncogenic role 28 
2 
ligand-dependent BMP signaling plays in suppressing differentiation in melanoma is a 29 
reiteration of its physiological roles during melanocyte development. 30 
 31 
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Introduction 35 
Tumor differentiation status is often an important prognostic factor in cancer. For many 36 
cancer types, tumors that are less differentiated are associated with a higher grade and 37 
worse prognosis compared to more differentiated tumors, which often follow indolent 38 
courses (Hoek et al., 2006; Rosai and Ackerman, 1979). In order to adopt a less 39 
differentiated state, a common event in cancer is downregulation of factors that drive 40 
differentiation of adult tissues (Chaffer et al., 2011; Dravis et al., 2018). This loss of pro-41 
differentiation factors is often coupled with an upregulation of other factors that are 42 
associated with embryonic or progenitor states (Caramel et al., 2013; Tulchinsky et al., 43 
2014). Thus, many de-differentiated and high-grade cancers have gene expression 44 
profiles associated with early development (O'Brien-Ball and Biddle, 2017). 45 
 46 
Developmental factors and pathways co-opted by cancers are often related to vital 47 
cellular functions, such as proliferation, migration, and differentiation (Caramel et al., 48 
2013; Casas et al., 2011; McConnell et al., 2019; Perego et al., 2018). Furthermore, the 49 
embryonic origin of specific tissues can impact the aggressive phenotypes tumors are 50 
able to acquire (Carreira et al., 2006; Gupta et al., 2005; Hoek and Goding, 2010). In 51 
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the case of melanoma, the cell of origin, the melanocyte, is derived from the neural 52 
crest, a highly migratory population of embryonic cells. Thus, melanomas are prone to 53 
early and aggressive metastasis, associated with the expression of neural crest 54 
migratory factors (Liu et al., 2014). Additionally, melanomas lacking differentiation 55 
exhibit more aggressive characteristics and are broadly more resistant to therapy 56 
(Fallahi-Sichani et al., 2017; Knappe et al., 2016; Landsberg et al., 2012; Mehta et al., 57 
2018; Muller et al., 2014; Shaffer et al., 2017; Zuo et al., 2018). While differentiation 58 
status is evidently important in the course of disease, the mechanisms by which 59 
melanomas and other cancers remain less differentiated are poorly understood. Since 60 
many of the factors associated with a lack of differentiation in these cancers are 61 
expressed and apparently function during embryogenesis, elucidating the 62 
developmental roles of these factors can give insight into their behaviors and roles in 63 
tumorigenesis and progression. 64 
 65 
A key pathway involved in early development and development of the neural crest is the 66 
bone-morphogenetic protein (BMP) pathway (reviewed in Kishigami and Mishina, 2005). 67 
The BMP pathway is activated by BMP ligands binding to BMP receptors, which can 68 
then phosphorylate SMAD1, SMAD5, and SMAD8 (also called SMAD9). 69 
Phosphorylated SMAD1/5/8 associates with co-SMAD4, forming a complex that can 70 
translocate to the nucleus and regulate expression of target genes. BMP signaling is 71 
important in early embryonic dorsoventral patterning and induction of the neural crest 72 
(Garnett et al., 2012; Hashiguchi and Mullins, 2013; McMahon et al., 1998; Schumacher 73 
et al., 2011). Following neural crest induction, BMP signaling has been implicated in 74 
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patterning within the neural crest and surrounding tissues, as well as development of 75 
nervous system- and musculoskeletal-related neural crest lineages (Hayano et al., 76 
2015; McMahon et al., 1998; Nikaido et al., 1997; Reichert et al., 2013; Valdivia et al., 77 
2016). While many developmental functions of BMP signaling are well characterized, 78 
the relationship of BMP signaling to the development of pigment cells from the neural 79 
crest is poorly understood. 80 
 81 
Our laboratory recently identified a BMP ligand, GDF6, that acts to suppress 82 
differentiation and cell death in melanoma (Venkatesan et al., 2018). We found that 83 
GDF6-activated BMP signaling in melanoma cells represses expression of MITF, a key 84 
regulator of melanocyte differentiation, leading to a less differentiated state. Here, we 85 
investigate the role of GDF6 and the BMP pathway in development of pigment cells in 86 
zebrafish. We show that BMP signaling regulates fate specification of neural crest-87 
derived pigment cell lineages and suppresses expression of mitfa, an ortholog of MITF. 88 
Furthermore, we show that disrupting BMP signaling alters fate specification between 89 
melanocyte and iridophore populations in the zebrafish. We determine that this shift in 90 
fate occurs at the level of an mitfa-positive pigment progenitor cell, and that BMP 91 
signaling acts through mitfa to direct mitfa-positive pigment progenitor cells to a specific 92 
fate. Altogether, these findings suggest pathologic BMP signaling in melanoma is a 93 
reiteration of normal physiologic function of BMP signaling during melanocyte 94 
development. 95 
 96 
Results 97 
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 98 
Loss of gdf6a leads to an increase in adult pigmentation 99 
To understand potential functions of gdf6a in the melanocyte lineage, we first 100 
determined if any alterations in pigment pattern were present in animals lacking gdf6a. 101 
In these studies, we used the gdf6as327 allele, hereafter referred to as gdf6a(lf), which 102 
encodes an early stop codon and has previously been shown to cause a complete loss 103 
of gdf6a function (Gosse and Baier, 2009). Previous studies have identified early roles 104 
for gdf6a during initial embryonic patterning, including dorsoventral patterning 105 
immediately following fertilization, thus gdf6a(lf) mutants have significantly decreased 106 
viability during the first 5 days post fertilization (Sidi et al., 2003). However, we found 107 
that a small proportion of gdf6a(lf) animals are able to survive early development and 108 
progress to adulthood. These gdf6a(lf) adult zebrafish had increased pigmentation when 109 
compared to wild-type zebrafish (Figure 1A). Furthermore, gdf6a(lf) adult zebrafish had 110 
qualitative disruption of the normal pigment pattern of both stripe and scale-associated 111 
melanocytes, and a significant increase in the number of scale-associated melanocytes 112 
as well as the overall scale area covered by melanin (Figure 1A,1B). These results 113 
indicate that gdf6a(lf) mutants have melanocyte defects. 114 
 115 
Loss of gdf6a or inhibition of BMP signaling leads to an increase in embryonic 116 
melanocytes 117 
Since zebrafish develop their adult pigment pattern during metamorphosis, it is possible 118 
gdf6a acts during this stage to change adult pigmentation, and not during initial pigment 119 
cell development in embryogenesis (Parichy and Spiewak, 2015; Patterson and 120 
Parichy, 2013; Quigley et al., 2004). To address this issue, we investigated whether 121 
6 
gdf6a(lf) caused embryonic pigmentation changes and, if so, whether any such changes 122 
were BMP-dependent. We crossed gdf6a(lf) heterozygotes and, in randomly selected 123 
progeny, quantified the number of melanocytes that developed by 5 days post-124 
fertilization (DPF). Following melanocyte quantification, we determined the genotype of 125 
each embryo. In parallel, we treated wild-type zebrafish during the period of neural crest 126 
induction and melanocyte specification (12 to 24 hours post fertilization) with a small 127 
molecule BMP inhibitor, DMH1, hereafter referred to as BMPi, and performed the same 128 
quantification of embryonic melanocytes (Hao et al., 2010). gdf6a(lf) homozygous 129 
animals developed approximately 40% more dorsal melanocytes by 5 DPF, when 130 
compared to sibling wild-type animals and gdf6a(lf) heterozygotes (Figures 1C,1D, 131 
Figure 1-figure supplement 1A). gdf6a(lf) animals also showed increased expression of  132 
mc1r, tyr, and tyrp1b, all markers of differentiated melanocytes, which is consistent with 133 
an increase in melanocyte number (Figure 1E). Furthermore, treatment with BMPi 134 
phenocopied the melanocyte changes observed in gdf6a(lf) mutants, coupled with a 135 
similar increase in expression of mc1r, tyr, and tyrp1b (Figures 1D and 1E). We 136 
observed a similar increase in total body melanocytes, indicating that there is an overall 137 
increase in melanocyte development instead of a failure of migration leading to a 138 
specific increase in dorsal melanocytes (Figure 1-figure supplement 1B). These results 139 
indicate gdf6a-activated BMP signaling normally acts in embryos to limit melanocyte 140 
development. 141 
 142 
gdf6 ortholog expression during neural crest development 143 
7 
Numerous BMP ligands are expressed during early embryogenesis and participate in 144 
multiple facets of development, including neural crest induction. It was previously shown 145 
that multiple BMP ligands are activated during zebrafish neural crest development 146 
(Reichert et al., 2013). Of those ligands investigated, only gdf6a and bmp6 were 147 
expressed in the neural crest, and only gdf6a activated BMP signaling within neural 148 
crest cells. An additional study identified dorsal expression of a zebrafish paralog of 149 
gdf6a, gdf6b, indicating it could potentially act in the neural crest (Bruneau and Rosa, 150 
1997). We verified gdf6b expression is restricted to the neural tube, and further 151 
determined gdf6b loss of function has no impact on pigment cell development by 152 
generating a gdf6b mutant, hereafter referred to as gdf6b(lf), and counting embryonic 153 
melanocytes (Figure 1-figure supplement 1D-G). We generated double mutants for both 154 
gdf6a(lf) and gdf6b(lf) to assess whether these paralogs functioned redundantly or could 155 
compensate for the loss of one another. Unfortunately, gdf6a(lf); gdf6b(lf) double 156 
mutants had significant morphologic defects and decreased viability such that we could 157 
not adequately compare melanocyte numbers in these animals (Figure 1-figure 158 
supplement 1H-I). However, because there were no pigmentation defects in gdf6b(lf) 159 
mutants and gdf6a(lf) pigmentation defects were the same severity as observed in 160 
animals treated with a pan-BMP inhibitor, it is likely that most, if not all, effects of BMP 161 
signaling on melanocyte development are directed by gdf6a. 162 
 163 
BMP inhibition increases mitfa-positive pigment cell progenitors in the neural crest 164 
We sought to determine the mechanism by which BMP signaling inhibits melanocyte 165 
development in embryos. Based on our experiments using BMPi, we suspected BMP 166 
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signaling acts during pigment cell development from the neural crest to prevent an 167 
increase in melanocytes. Following induction, neural crest cells undergo proliferation, 168 
followed by fate restriction and specification, in which individual cells become less and 169 
less multipotent until a single possible fate remains (Jin et al., 2001; Lewis et al., 2004; 170 
Nagao et al., 2018). In many cases, specification to the ultimate lineage is determined 171 
by activation of an individual or a group of lineage-specific factors (Sauka-Spengler et 172 
al., 2007). For pigment cells, fate specification is dependent on integration of many 173 
signaling factors, including BMP and Wnt signaling, as well as key transcription factors, 174 
such as AP2α, AP2ε, SOX-, PAX-, and FOX-family transcription factors (Garnett et al., 175 
2012; Ignatius et al., 2008; Lister et al., 2006; Sato et al., 2005; Southard-Smith et al., 176 
1998; Thomas and Erickson, 2009; Van Otterloo et al., 2010). In zebrafish, specification 177 
of the melanocyte lineage depends on upregulation of sox10 and downregulation of 178 
factors inhibiting differentiation, such as foxd3 (Curran et al., 2010; Curran et al., 2009; 179 
Dutton et al., 2001). Following sox10 upregulation, a subset of sox10-positive cells can 180 
activate pigment lineage markers associated with melanocytes, iridophores, and 181 
xanthophores (Elworthy et al., 2003; Fadeev et al., 2016; Nagao et al., 2018; Nord et 182 
al., 2016; Petratou et al., 2018). mitfa is a key factor that is expressed early in pigment 183 
progenitor cells (Lister et al., 1999). Based on this framework, we hypothesized two 184 
potential mechanisms by which supernumerary melanocytes are generated: 1) an 185 
increase in proliferation of either neural crest cells or pigment progenitor cells, or 2) an 186 
increase in the proportion of neural crest cells that are specified to become pigment 187 
progenitor cells. To assess changes in proliferation of neural crest cells and pigment 188 
cells, we analyzed cell cycle profiles using flow cytometry. Embryos expressing 189 
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reporters for neural crest cells (Tg(crestin:eGFP)) or pigment progenitor cells 190 
(Tg(mitfa:eGFP)) were treated with BMPi from 12 to 24 HPF, during neural crest 191 
development and specification (Curran et al., 2009; Kaufman et al., 2016). Embryos 192 
were dissociated, stained with DAPI, and analyzed for DNA content of neural crest cells 193 
or pigment progenitor cells as defined by the fluorescent GFP marker (Figure S2A). We 194 
observed no increase in the percent of S/G2/M cells in either population, indicating no 195 
apparent change to cell cycle distribution of either neural crest cells or pigment 196 
progenitor cells (Figure 2-figure supplement 1B-C). To verify these findings reflected no 197 
change in proliferation rate, we performed a 5-ethynyl-2’-deoxyuridine (EdU) 198 
incorporation assay. We treated Tg(crestin:eGFP) or Tg(mitfa:eGFP) embryos with 199 
BMPi or vehicle control along with EdU during early (12-14 HPF), middle (16-18 HPF), 200 
and late (20-22 HPF) stages of neural crest and pigment cell development (Figure 2-201 
figure supplement 1D-E). We observed no differences in EdU incorporation between 202 
BMPi-treated and vehicle control groups, indicating no change in proliferation rates of 203 
either crestin:eGFP-positive neural crest cells or mitfa:eGFP-positive pigment progenitor 204 
cells (Figure 2-figure supplement 1F). Without an obvious increase in proliferation, we 205 
tested the hypothesis that a change in specification results in increased melanocytes. 206 
To assess changes in specification of neural crest cells into pigment progenitor cells, we 207 
utilized reporter embryos marking neural crest cells in red (Tg(crestin:mCherry)) and 208 
pigment progenitor cells in green (Tg(mitfa:eGFP)) (Figure 2A). Using these reporters, 209 
neural crest cells not committed to the pigment cell lineage are crestin:mCherry single-210 
positive, whereas crestin:mCherry/mitfa:eGFP double-positive cells are those newly 211 
committed to the pigment cell lineage. We treated embryos containing both reporter 212 
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transgenes with BMPi from 12 to 24 HPF, during neural crest development and 213 
specification. At 24 HPF, we dissociated embryos and analyzed cells for fluorescent 214 
marker expression by flow cytometry (Figure 2A). Embryos treated with BMPi showed 215 
approximately a 1.5-fold increase in the percentage of crestin:mCherry/mitfa:eGFP 216 
double-positive cells per total crestin:mCherry-positive cells (Figure 2B, 2C). We further 217 
verified a change in specification by staining BMPi- or vehicle-treated Tg(crestin:eGFP) 218 
embryos with anti-Mitfa antibody and assessed the proportion of crestin:eGFP-positive 219 
cells that stained positive for Mitfa (Figure 2D). We observed a 1.3-fold increase in the 220 
proportion of Mitfa/crestin:eGFP double-positive cells per total crestin:eGFP-positive 221 
cells in animals treated with BMPi compared to vehicle control (Figure 2E). Altogether 222 
these results suggest that an increase in embryonic melanocytes is caused by an 223 
increase in the proportion of neural crest cells specified as pigment progenitor cells, 224 
rather than a change in proliferation of either neural crest or pigment progenitor cells. 225 
 226 
BMP signaling in mitfa-expressing pigment progenitor cells can alter melanocyte 227 
development in embryogenesis 228 
Because we observed an impact of BMP signaling on neural crest-to-pigment progenitor 229 
cell specification, we explored the relationship between gdf6a and mitfa expression. 230 
First, using whole-mount in situ hybridization (Figure 3A), we found that the 231 
anteroposterior expression domains of gdf6a and mitfa were mostly, if not completely, 232 
non-overlapping. As described previously (Reichert et al., 2013; Rissi et al., 1995), 233 
gdf6a was expressed in the anterior half of the embryo in the neural crest at 12 HPF, 234 
shortly following its induction. Consistent with previous observations (Lister et al., 1999), 235 
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mitfa was not expressed at this time. At 18 HPF, gdf6a was absent from the anterior 236 
neural crest, but instead was restricted to the posterior half of the embryo with 237 
expression apparent in the hypochord and epidermal cells (Rissi et al., 1995). At 24 238 
HPF, gdf6a expression was further restricted to the posterior end of the embryo and 239 
mitfa expression expanded posteriorly to a commensurate degree. 240 
 241 
To quantify changes in expression of gdf6a and mitfa specifically in neural crest cells, 242 
we isolated eGFP-positive cells from Tg(crestin:eGFP) embryos at 16 HPF and 22 HPF 243 
by FACS. We analyzed the relative levels of gdf6a and mitfa expression using qRT-244 
PCR and found that gdf6a expression is relatively higher than mitfa at 16 HPF, while 245 
mitfa expression is relatively higher at 22 HPF, indicating an inverse correlation of 246 
expression over the course of neural crest development (Figure 3B). The reciprocal 247 
nature of gdf6a and mitfa expression changes is consistent with the possibility that 248 
gdf6a-driven BMP signaling acts in neural crest cells to repress mitfa expression and 249 
prevent excess pigment progenitor cells from being specified. However, we also 250 
considered the possibility that BMP signaling is active in mitfa-positive cells and affects 251 
the fates of these cells. To determine if BMP signaling is active in mitfa-positive cells, 252 
we stained Tg(mitfa:eGFP) zebrafish with antibodies against phosphorylated-SMAD-253 
1/5/8 (pSMAD). We verified specificity of the anti-pSMAD antibody using BMPi treated 254 
embryos (Figure 3-figure supplement 1). 30% of mitfa-expressing cells on the leading, 255 
posterior edge of the mitfa expression domain had nuclear-localized pSMAD staining, 256 
whereas only 7% of mitfa-expressing cells in regions anterior to the leading edge 257 
showed nuclear pSMAD staining (Figure 3C and 3D). These results suggest BMP 258 
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signaling is active as mitfa-expressing cells first arise in the neural crest, but is turned 259 
off in such cells as development proceeds.  260 
 261 
To assess if BMP activity in mitfa-expressing cells can impact melanocyte development, 262 
we directly altered BMP activity in these cells. We first generated a stably transgenic 263 
zebrafish line expressing gdf6a under the control of the mitfa promoter (Tg(mitfa:gdf6a)) 264 
to increase gdf6a expression in mitfa-expressing cells. Embryos expressing the 265 
Tg(mitfa:gdf6a) transgene developed fewer melanocytes than non-transgenic sibling 266 
controls (Figure 4A). To alter BMP signaling in a cell-autonomous manner within mitfa-267 
expressing cells, we used the miniCoopR system in two complementary approaches: a) 268 
to express a dominant negative BMP receptor (dnBMPR), which suppresses 269 
intracellular BMP activity, and b) to express a phospho-mimetic variant of SMAD1 270 
(SMAD1-DVD) to constitutively activate intracellular BMP activity (Ceol et al., 2011; 271 
Nojima et al., 2010; Pyati et al., 2005). We injected mitfa(lf) animals with miniCoopR-272 
dnBMPR, miniCoopR-SMAD1-DVD, or control miniCoopR-eGFP (Figure 4B). At 5 DPF, 273 
we scored animals for rescue of melanocytes. Animals injected with miniCoopR-274 
dnBMPR showed a rescue rate of 79% as compared to 29% of miniCoopR-eGFP-275 
injected animals. Furthermore, animals injected with miniCoopR-SMAD1-DVD showed 276 
a 15% rescue rate (Figure 4C). Together these results suggest BMP signaling is active 277 
in mitfa-expressing cells and modulating BMP signaling can alter the fate of these mitfa-278 
expressing cells during development. Thus, gdf6a-driven BMP signaling can both limit 279 
the number of mitfa-expressing cells arising from the neural crest but also act in mitfa-280 
expressing pigment progenitor cells to influence their development into melanocytes. 281 
13 
 282 
Iridophores, but not other neural crest derivatives, are reduced upon gdf6a loss 283 
Because we observed no change in proliferation of crestin- or mitfa-positive 284 
populations, but the number of melanocytes developing from these precursors was 285 
increased, we questioned whether this increase corresponded with a commensurate 286 
loss of a related pigment or other neural crest-derived cell type. To determine what cells 287 
may be impacted, we looked for transcriptional changes in markers of other, related 288 
neural crest derivatives as well as known neural crest factors important in specifying 289 
different cell fates. We isolated RNA from gdf6a(lf) and wild-type embryos at 5 DPF. 290 
Additionally, we isolated RNA from embryos treated with a BMPi or vehicle control. We 291 
performed qRT-PCR for markers of neural crest derivatives, including mbpa for glial 292 
cells, pomca for adrenal medullary cells, neurog1 for neuronal cells, aox5 for 293 
xanthophores, and pnp4a for iridophores, as well as sox10 and foxd3 (Fadeev et al., 294 
2016; McGraw et al., 2008; Parichy et al., 2000; Thomas and Erickson, 2009). As a 295 
control, we used a chondrocyte marker, col2a1a, as craniofacial development has 296 
previously been described to be disrupted by gdf6a loss (Reed and Mortlock, 2010). Per 297 
our previous analysis, gdf6a(lf) mutants and BMPi-treated embryos demonstrated an 298 
increase in expression of the melanocyte markers mc1r, tyr, and tyrp1b (Figure 1E). 299 
And as predicted based on previous literature, gdf6a(lf) mutants and BMPi-treated 300 
embryos showed a decrease in expression of the chondrocyte marker, col2a1a. We 301 
observed no changes in foxd3 expression, but observed a slight downregulation of 302 
sox10 (Figure 5-figure supplement 1A), previously shown to be downregulated upon 303 
GDF6 knockdown in melanoma cells (Venkatesan et al., 2018). Because foxd3 has 304 
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previously been shown to be related to both BMP signaling in neural crest induction and 305 
pigment cell development (Curran et al., 2010; Curran et al., 2009; Stewart et al., 2006), 306 
we questioned if foxd3 may have a functional role in mediating the effect of BMP 307 
signaling on melanocyte development despite no change in expression. We treated 308 
foxd3(lf) (Stewart et al., 2006) embryos with BMPi and assessed melanocyte 309 
development (Figure 5-figure supplement 1B). We observed a comparable increase in 310 
melanocytes in foxd3(lf) and sibling control animals, indicating BMP signaling acts 311 
independently of foxd3 to alter melanocyte development. Despite a downregulation of 312 
sox10 in gdf6a mutants and BMPi-treated embryos, we still observed an increase in 313 
mitfa expression and markers of melanocyte differentiation, and an increase in the 314 
number of melanocytes.  315 
 316 
In our evaluation of neural crest derivative populations, markers for neuronal, glial, 317 
adrenal medullary, and xanthophore lineages were no different in gdf6a compared to 318 
wild-type animals (Figure 5A). Similar results were obtained in animals treated with a 319 
BMPi, with the exception of a change in mbpa expression, a marker for glial cells. 320 
Previous studies have shown glial cell development is regulated in part by BMP activity 321 
(Jin et al., 2001). Since mbpa expression was unchanged in gdf6a(lf) animals, this 322 
suggests another BMP ligand is involved in activating BMP signaling to promote glial 323 
cell development. For neuronal and xanthophore cell populations, we verified that the 324 
expression profile correlated with cell numbers or development of key structures. We 325 
treated animals with BMPi or vehicle and stained with anti-HuC/D antibody to label 326 
neuronal cells in the dorsal root ganglia and developing gastrointestinal tract (Lister et 327 
15 
al., 2006) (Figure 5-figure supplement 1C-E). We detected no difference in dorsal root 328 
ganglia and enteric neuron development between each group. We imaged animals 329 
stably expressing Tg(aox5:PALM-eGFP) to label xanthophores and found no qualitative 330 
difference in xanthophores between BMPi- and vehicle-treated groups (Eom and 331 
Parichy, 2017) (Figure 5-figure supplement 1F). We further evaluated mitfa-positive 332 
cells associated with the dorsal root ganglion that have previously been connected to 333 
formation of adult pigment and are proposed to be melanocyte stem cells (Dooley et al., 334 
2013; Hultman et al., 2009; Singh et al., 2016). Using Tg(mitfa:eGFP) embryos, we 335 
observed an increase in these DRG-associated, mitfa:eGFP-positive cells, suggesting 336 
that BMPi not only increases differentiated embryonic melanocytes but also cells that 337 
underlie adult pigmentation (Figure 5-figure supplement 1G). 338 
 339 
In our transcriptional analyses of gdf6a(lf) and BMPi-treated embryos, we observed a 340 
decrease in expression of pnp4a, a marker for the iridophore lineage, indicating a 341 
potential deficit of iridophore development (Figure 5A). Since pnp4a is expressed in 342 
other developing cells and tissues, such as retinal cell populations, we wanted to 343 
confirm these changes were specific to a deficit in neural crest-derived body iridophores 344 
(Cechmanek and McFarlane, 2017; Lopes et al., 2008; Petratou et al., 2018). We 345 
quantified the number of dorsal iridophores that developed in gdf6a(lf) embryos (Figure 346 
5B) and embryos treated with BMPi (Figure 5C) at 5 DPF, using incident light to 347 
highlight embryonic iridophores. Embryos developed 32% and 27% fewer iridophores 348 
with gdf6a(lf) or BMPi treatment, respectively. Together, these results indicate that 349 
gdf6a-driven BMP signaling promotes iridophore development. 350 
16 
 351 
BMP inhibition increases the likelihood a multipotent precursor will develop into a 352 
melanocyte 353 
Melanocytes and iridophores have previously been shown to develop from mitfa-354 
expressing pigment progenitor cells (Curran et al., 2010; Curran et al., 2009). To 355 
determine if BMP signaling regulates fate specification of melanocytes and iridophores 356 
from mitfa-expressing pigment progenitor cells, we performed lineage tracing. We 357 
injected Tg(ubi:switch) embryos, which stably express a ubi:loxp-GFP-STOP-loxp-358 
mCherry-STOP transgene (Mosimann et al., 2011) with a mitfa:Cre-ERT2 transgene to 359 
generate mosaic expression of Cre-ERT2 in mitfa-positive cells (Figure 6A). Injected 360 
embryos were treated with BMPi and hydroxytamoxifen (4-OHT), the latter to allow 361 
nuclear localization of Cre and generate recombinant events in individual mitfa-362 
expressing pigment progenitor cells. Since these mitfa-expressing pigment progenitor 363 
cells are transient, 4-OHT treatment was limited to 12 to 24 HPF, with thorough embryo 364 
water exchange to wash out the drug and prevent recombinant events after 365 
specification. At 5 DPF, embryos with individual recombinant events, indicated by single 366 
mCherry-positive cells, were evaluated for the fate of those cells. In animals treated with 367 
BMPi, we observed an increase in the ratio of labeled melanocytes to iridophores as 368 
compared to vehicle-treated controls (Figure 6B, Figure 6-figure supplement 1). This 369 
result suggests that BMP signaling normally promotes the development of mitfa-370 
expressing pigment progenitor cells into iridophores at the expense of melanocytes. 371 
 372 
17 
BMP signaling represses mitfa expression within neural crest and pigment progenitor 373 
cells 374 
Previous studies have indicated that the expression level of mitfa within pigment 375 
progenitor cells is important in specifying a melanocyte versus iridophore fate (Curran et 376 
al., 2010; Curran et al., 2009). Cells with a higher level mitfa expression are more likely 377 
to become melanocytes, while those that downregulate mitfa are more likely to become 378 
iridophores. Since gdf6a(lf) and BMP-inhibited embryos have excess melanocytes and 379 
fewer iridophores, we hypothesized that this phenotype resulted from disrupted 380 
regulation of mitfa expression in these embryos. This hypothesis was driven, in part, by 381 
our previous data in human melanoma cells, in which knockdown of GDF6 decreased 382 
phospho-SMAD1/5/8 binding at the MITF locus and increased MITF expression 383 
(Venkatesan et al., 2018). We first determined the potential for mitfa to be regulated in a 384 
similar manner as MITF. We first looked at the flanking regions of both the MITF and 385 
mitfa loci for orthologous genes (Catchen et al., 2009). We found many of the same 386 
orthologs present near both loci, indicating a syntenic relationship (Figure 7-figure 387 
supplement 1A). We did not find conservation in mitfa of the phospho-SMAD-binding 388 
region defined in mammalian cells. However, in mitfa we did identify phospho-SMAD 389 
binding motfs (GC-SBM) similar to the one present in the mammalian phospho-SMAD-390 
binding region (Morikawa et al., 2011), as well as additional phospho-SMAD-binding 391 
motifs that have been defined previously (Jonk et al., 1998). The presence of such sites 392 
suggests the potential for mitfa to be directly regulated by phospho-SMAD1/5/8 similarly 393 
to MITF (Figure 7-figure supplement 1B). To assess mitfa levels within neural crest cells 394 
and mitfa-expressing pigment progenitor cells, we treated Tg(crestin:eGFP) and 395 
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Tg(mitfa:eGFP) embryos with BMPi as previously described. We dissociated embryos 396 
and used fluorescence-activated cell sorting (FACS) to isolate crestin:eGFP-positive or 397 
mitfa:eGFP-positive cells. We then assessed mitfa transcript levels in each population 398 
by qRT-PCR. Treatment with BMPi led to approximately 3-fold and 6-fold increases in 399 
mitfa expression in crestin:eGFP-positive and mitfa:eGFP-positive cells, respectively 400 
(Figure 7A). To explore this question on a single-cell level and analyze Mitfa protein 401 
levels, we stained BMPi-treated and vehicle-treated Tg(crestin:eGFP) embryos with an 402 
anti-Mitfa antibody (Figure 7B) (Venkatesan et al., 2018). In BMPi-treated animals, we 403 
observed a 2.5-fold increase in Mitfa staining intensity in crestin:eGFP-positive cells, 404 
indicating inhibition of BMP signaling leads to an increase in Mitfa protein in pigment 405 
progenitor cells at a single-cell level (Figure 7C). Furthermore, those cells that were 406 
Mitfa-positive and crestin:eGFP-negative showed a 1.7-fold increase in Mitfa staining 407 
intensity, indicating inhibition of BMP signaling also leads to an increase in Mitfa protein 408 
following specification of pigment cells (Figure 7B, 7C). Together, these results indicate 409 
BMP signaling suppresses mitfa expression in cells during specification of pigment cell 410 
lineages. 411 
 412 
Regulation of pigment cell fate by BMP signaling is dependent on mitfa 413 
If deregulated mitfa expression is critical to the phenotypic defects observed upon 414 
inhibition of BMP signaling, then these defects should be dependent on mitfa function. 415 
To determine whether mitfa is indeed responsible for mediating the shift in cell fate 416 
regulated by BMP activity, we treated mitfa(lf) embryos with BMPi. As mitfa is necessary 417 
for the specification of all body melanocytes, mitfa(lf) animals do not develop any 418 
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melanocytes during embryogenesis or through adulthood. However, these animals can 419 
develop iridophores and develop a greater number of iridophores at baseline than their 420 
wild-type counterparts (Lister et al., 1999). We hypothesized that, if an elevation of mitfa 421 
expression in BMPi-treated embryos was required to shift pigment progenitor cell fates 422 
from iridophores to melanocytes, there would be no decrease in the number of 423 
iridophores when mitfa(lf) embryos were treated with BMPi. Indeed, BMPi-treated 424 
embryos showed no difference in the number of iridophores compared to vehicle-425 
treated controls (Figure 7D, 7E). Together, these results indicate that BMP inhibition 426 
requires mitfa to direct pigment progenitor cells away from iridophore fate. 427 
 428 
Discussion 429 
Our results elucidate a role for gdf6a-activated BMP signaling in suppressing 430 
melanocyte development from the neural crest during embryogenesis. Inhibition of BMP 431 
signaling leads to an increase of neural crest cells expressing mitfa, affecting the 432 
proportion of neural crest cells specified as pigment progenitor cells. Additionally, in 433 
BMP-inhibited embryos these mitfa-positive pigment progenitor cells demonstrate an 434 
increased propensity to become melanocytes, instead of iridophores. Cells in BMP-435 
inhibited embryos have increased expression of mitfa, and the function of mitfa is 436 
required for the reduction of iridophores observed in BMP-inhibited embryos. Based on 437 
these findings, we propose that gdf6a-activated BMP signaling normally represses mitfa 438 
expression, limiting both the development of pigment progenitor cells from the neural 439 
crest and the specification of melanocytes from these pigment progenitor cells. As 440 
discussed below, MITF is downregulated by GDF6-activated BMP signaling to prevent 441 
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melanocytic differentiation in melanomas (Venkatesan et al., 2018). The function we 442 
have defined for gdf6a-activated BMP signaling in development suggests that its activity 443 
is co-opted in tumors to prevent differentiation of melanoma cells. 444 
 445 
Regulation of pigment cell fate by BMP signaling 446 
Our studies indicate gdf6a-activated BMP signaling can regulate pigment cell 447 
development from the neural crest in two ways. First, BMP signaling restricts the 448 
number of neural crest cells that transition into mitfa-positive pigment cell progenitors. 449 
When BMP signaling is abrogated, additional cells adopt a pigment progenitor fate, 450 
which likely is a source of supernumerary melanocytes. Second, BMP signaling biases 451 
the fate choice of mitfa-positive progenitor cells. In BMP-deficient embryos, mitfa-452 
positive progenitor cells more often become melanocytes and less often become 453 
iridophores. Previous studies have suggested a common melanocyte-iridophore 454 
progenitor (Curran et al., 2010; Curran et al., 2009; Petratou et al., 2018), and our data 455 
support the existence of such a progenitor and indicate that it is mitfa-expressing and 456 
influenced by BMP signaling. These studies implicate foxd3 (Curran et al., 2010; Curran 457 
et al., 2009) or some other unknown factor (Petratou et al., 2018) that regulates the fate 458 
of this progenitor. Our data indicate BMP signaling can act independently of foxd3 in 459 
impacting melanocyte development, thus suggesting BMP signaling may directly 460 
suppress the melanocyte fate or act indirectly through another factor. While BMP 461 
signaling regulates the fate of a common melanocyte-iridophore precursor, the 462 
decrease in the number of iridophores cannot fully account for the number of 463 
melanocytes gained in gdf6a(lf) and BMPi-treated embryos. Because gdf6a(lf) and 464 
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BMPi-treatment are potentially impacting the entirety of neural crest development, other 465 
neural crest cells may be mis-specified to the melanocyte lineage. This misspecification 466 
could account for the discrepancy between the gain of melanocytes and loss of 467 
iridophores. If misspecification of other neural crest cells is occurring, other neural crest 468 
lineages could show a deficit. However, in our assays evaluating other lineages, we 469 
detected no deficits outside of a loss of iridophores. Among several possibilities, the 470 
deficit may be present in a neural crest lineage we did not directly measure. 471 
Alternatively, deficits in other neural crest lineages may be small and distributed across 472 
multiple other lineages, such that our assays are unable to detect those subtle changes. 473 
Lastly, proliferation within the neural crest and of neural crest derivatives following 474 
migration from the crest is known to occur (Dougherty et al., 2013; Gianino et al., 2003), 475 
and it is possible that such proliferation could compensate for any deficit. In summary, 476 
the supernumerary melanocytes observed in gdf6a(lf) and BMPi-treated embryos are 477 
likely to arise from some combination of neural crest cells that are shunted to the 478 
pigment cell lineage and melanocyte-iridophore precursors that preferentially adopt a 479 
melanocyte fate. 480 
 481 
Regulation of mitfa by BMP signaling 482 
Our studies identify gdf6a-activated BMP signaling as a regulator of mitfa during 483 
pigment cell development in zebrafish. Previous studies have identified roles for gdf6a 484 
in the preplacodal ectoderm, retinal cell survival, and craniofacial development in 485 
zebrafish, while others have broadly connected BMP signaling to fate determination and 486 
cell survival in the neural crest in other model systems (French et al., 2009; Gosse and 487 
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Baier, 2009; Hanel and Hensey, 2006; Jin et al., 2001; Reed and Mortlock, 2010; 488 
Reichert et al., 2013). However, the specific role of BMP signaling and of gdf6a on 489 
pigment cell development has heretofore been uncharacterized. Our analyses indicate 490 
that gdf6a is expressed in neural crest cells prior to the anteroposterior onset of mitfa 491 
expression. In addition, we observed an overlap of BMP activity and mitfa expression at 492 
the leading edge of the anteroposterior mitfa progression. When BMP signaling was 493 
inhibited, we found increased expression in neural crest cells of mitfa RNA and Mitfa 494 
protein. Together, these results suggest that gdf6a-driven BMP signaling regulates 495 
expression of mitfa and, consequently, directs fates adopted by mitfa-expressing cells. 496 
We speculate that such a role underlies the excess melanocytes observed in gdf6a(lf) 497 
and BMPi-treated embryos. In the absence of gdf6a and BMP signaling, increased 498 
expression of mitfa could lead to a greater proportion of neural crest cells adopting a 499 
pigment cell fate and could lead to a greater propensity of melanocyte-iridophore 500 
precursors adopting a melanocyte fate. These findings are consistent with what has 501 
previously been established in human melanoma cells, where GDF6-activated BMP 502 
signaling has been shown to promote pSMAD binding to MITF and is suspected to 503 
directly regulate MITF expression (Venkatesan et al., 2018). Our results support this 504 
regulatory role and provide a developmental context in vivo to understand why GDF6-505 
activated BMP signaling is able to regulate MITF in melanoma cells. 506 
 507 
Reiteration of normal physiologic function in melanoma 508 
GDF6 and BMP signaling were previously described in melanoma to suppress 509 
differentiation through binding of pSMAD to MITF and corresponding repression of MITF 510 
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expression (Venkatesan et al., 2018). Results from the current study indicate gdf6a and 511 
BMP signaling likely act in a similar fashion during development to repress expression 512 
of MITF, either directly or indirectly, leading to suppression of melanocyte specification 513 
and differentiation from the neural crest. Together, these findings suggest BMP activity 514 
in melanoma is a recapitulation of normal regulatory functions executed by gdf6a and 515 
BMP signaling during pigment cell development. It has been previously established that 516 
lineage programs can be co-opted by cancers to promote pro-tumorigenic 517 
characteristics (Carreira et al., 2006; Gupta et al., 2005). These programs activate EMT 518 
factors, such as TWIST1 and SNAI2, and factors associated with neural crest 519 
multipotency, such as SOX10, to promote invasiveness, proliferative capacity, 520 
metastatic capability, and therapeutic resistance (Caramel et al., 2013; Casas et al., 521 
2011; Shakhova et al., 2015). However, it is unclear if these factors have similar 522 
regulation between normal development and melanoma. Here, we have described a 523 
developmental role for GDF6 that is reiterated in a pathologic process in disease. 524 
Because initiation and maintenance of neural crest gene expression has been shown to 525 
be important in melanoma, a better understanding of how regulation occurs during 526 
development may have clinical implications (Kaufman et al., 2016). Our findings indicate 527 
BMP signaling has a regulatory role over key differentiation genes during melanocyte 528 
development from the neural crest. Many studies have implicated expression of neural 529 
crest and melanocyte factors during many phases of melanoma, including initiation, 530 
progression, invasion, metastasis, and therapeutic resistance of melanoma (Carreira et 531 
al., 2006; Fallahi-Sichani et al., 2017; Gupta et al., 2005; Kaufman et al., 2016; Shaffer 532 
et al., 2017). Taken together, these findings suggest therapeutic targeting of GDF6 or 533 
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BMP signaling would likely have a positive impact on prognosis and outcome in 534 
melanoma patients by promoting differentiation in tumors.  535 
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Methods 569 
Key Resources Table 570 
Key Resources Table 
Reagent 
type 
(species) 
or 
resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
information 
strain, 
strain 
background 
(Danio 
rerio) 
gdf6a(lf) 
Gosse et al., 
2009 -- 
PMID: 
19164594 
 gdf6as327 allele 
strain, 
strain 
background 
gdf6b(lf) This paper  
Generated using 
Golden Gate 
TALEN kit – see 
26 
(Danio 
rerio) 
materials and 
methods 
strain, 
strain 
background 
(Danio 
rerio) 
Tg(mitfa:eGFP) 
Curran et 
al., 2009 --
PMID: 
19527705  
  
strain, 
strain 
background 
(Danio 
rerio) 
Tg(crestin:eGFP) 
Kaufman et al., 
2016 -- PMID: 
26823433 
 
  
strain, 
strain 
background 
(Danio 
rerio) 
Tg(crestin:mCherry
) 
Kaufman et al., 
2016 -- PMID: 
26823433 
 
  
strain, 
strain 
background 
(Danio 
rerio) 
Tg(ubi:switch) 
Mosimann 
et al., 2011 -
- PMID: 
21138979 
  
strain, 
strain 
background 
(Danio 
rerio) 
Tg(mitfa:gdf6a) This paper  
gdf6a expressed 
under the mitfa 
promoter, 
generated using 
Tol2Mediate 
transgenesis – see 
materials and 
methods. 
strain, 
strain 
background 
(Danio 
rerio) 
mitfa(lf) 
Lister et al., 
1999 -- 
PMID: 
10433906 
 nacre mutant 
strain, 
strain 
background 
(Danio 
rerio) 
foxd3(lf) 
Stewart et 
al., 2006 -- 
PMID: 
16499899 
 sym1 mutant 
antibody 
Phospho-
SMAD1/5/9, rabbit 
monoclonal 
CellSignalin
g 
#13820 1:200 
27 
antibody 
Mitfa, rabbit 
polyclonal 
Venkatesan 
et al. 
N/A 
1:100 
antibody 
GFP, mouse 
monoclonal 
Thermo-
Fisher 
#MA5-15256 
1:500 
antibody 
Goat anti-Mouse 
IgG-Alexafluor 488 
Thermo-
Fisher 
#A-11001 
1:300 
antibody 
Goat anti-Rabbit IgG-
Alexafluor 555 
Thermo-
Fisher 
#A-21428 
1:300 
antibody 
Anti-DIG-AP Fab 
Fragments 
Roche #1109327491
0 1:1000 
antibody 
HuC/HuD antibody, 
mouse monoclonal 
Thermo-
Fisher 
#A-21271 
1:100 
recombinan
t DNA 
reagent 
pENTRP4P1r-mitfa Ceol et al., 
2011 -- PMID: 
21430779 
  
recombinan
t DNA 
reagent 
pDONR221-gdf6b Venkatesan 
et al., 2017 -- 
PMID: 
29202482 
  
recombinan
t DNA 
reagent 
pDONR221-gdf6a This paper 
 
Tol2 p221 entry 
vector containing 
gdf6a 
recombinan
t DNA 
reagent 
pDONR221-Cre-
ERT2 
Mosimann 
et al., 2011 -
- PMID: 
21138979 
  
recombinan
t DNA 
reagent 
miniCoopR Ceol et al., 
2011 -- PMID: 
21430779 
  
recombinan
t DNA 
reagent 
pcsDest2 Villefranc et 
al., 2007 -- 
PMID: 
17948311 
  
recombinan
t DNA 
reagent 
p3E-polyA Tol2Kit (Kwan 
et al., 2007) -- 
PMID: 
17937395 
  
recombinan
t DNA 
reagent 
pME-eGFP Tol2Kit (Kwan 
et al., 2007) -- 
PMID: 
  
28 
17937395 
recombinan
t DNA 
reagent 
pDestTol2CG2 (395) Tol2Kit (Kwan 
et al., 2007) -- 
PMID: 
17937395 
  
recombinan
t DNA 
reagent 
pDestTol2pA2 (394) Tol2Kit (Kwan 
et al., 2007) -- 
PMID: 
17937395 
  
recombinan
t DNA 
reagent 
miniCoopR-
mitfa:dnBMPR:pA 
This paper 
 
miniCoopR vector 
expressing 
dominant negative 
BMP receptor; 
generated by 
multisite Gateway 
recombinan
t DNA 
reagent 
miniCoopR-
mitfa:eGFP:pA 
This paper 
 
miniCoopR vector 
expressing control 
eGFP; generated 
by multisite 
Gateway 
recombinan
t DNA 
reagent 
miniCoopR-
mitfa:SMAD1-
DVD:pA 
This paper 
 
miniCoopR vector 
expressing 
constitutively 
active SMAD1; 
generated by 
multisite Gateway 
recombinan
t DNA 
reagent 
395-mitfa:gdf6a:pA This paper 
 
pDEST vector 
expressing gdf6a 
under mitfa 
promoter; 
generated by 
multisite Gateway 
recombinan
t DNA 
reagent 
395-mitfa:Cre-
ERT2:pA 
This paper 
 
pDEST vector 
expression 
CreERT2 under 
mitfa promoter; 
generated by 
multisite Gateway 
recombinan
t DNA 
reagent 
pcsDest2-gdf6a This paper 
 
pDEST vector 
used to generate 
gdf6a probes; 
generated by 
Gateway reaction 
29 
recombinan
t DNA 
reagent 
pcsDest2-gdf6b This paper 
  
 pDEST vector 
used to generate 
gdf6b probes; 
generated by 
Gateway reaction 
sequence-
based 
reagent 
 qPCR & 
Genotyping 
Primers 
    
See 
Supplementary file 
1 for primer 
sequences 
commercial 
assay or kit 
LR Clonase 2+ Kit Thermo-
Fisher 
#12538120 
 
commercial 
assay or kit 
LR Clonase Kit Thermo-
Fisher 
#11791043 
 
commercial 
assay or kit 
Golden Gate TALEN 
and TAL Effector Kit 
2.0 
Addgene #1000000024 
 
commercial 
assay or kit 
mMessage 
mMachine Kit 
Ambion #AM1340 
 
commercial 
assay or kit 
DIG RNA Labeling 
Kit 
Roche #1117502591
0  
commercial 
assay or kit 
SuperScript III First 
Strand Synthesis 
Thermo-
Fisher 
#18080051 
 
commercial 
assay or kit 
SYBR Green Master 
Mix 
Applied 
Biosystems 
4344463 
  
commercial 
assay or kit 
Click-it EdU Cell 
Proliferation Kit for 
Imaging, AF 555 
 Invitrogen  C10338   
chemical 
compound, 
drug 
DMH1 Sigma Aldrich #D8946 
 
chemical 
compound, 
drug 
Hydroxytamoxifen (4-
OHT) 
Sigma Aldrich #H7904 
 
30 
chemical 
compound, 
drug 
Epinephrine Acros 
Organics 
#430140250 
 
chemical 
compound, 
drug 
DAPI Life 
Technologies 
#D1306 
 
chemical 
compound, 
drug 
Hoechst-33342 Life 
Technologies 
#H3570 
 
chemical 
compound, 
drug 
Pronase Sigma Aldrich #1016592100
1  
chemical 
compound, 
drug 
Trizol Ambion #15596026 
  
software, 
algorithm 
Microsoft Excel 
    
Microsoft Excel 
(Office 2016), 
www.microsoft.co
m 
software, 
algorithm 
Graphpad Prism 7 
    
 GraphPad Prism 7 
for Windows, 
GraphPad 
Software, 
www.graphpad.com 
software, 
algorithm 
Image J 
    
 (Schindelin et al., 
2012) 
software, 
algorithm 
Leica LAS X 
    
 Leica LAS X for 
Windows, Leica 
Microsystems, 
www.leica-
microsystems.com 
software, 
algorithm 
FlowJo 
    
 Flow Jo v10 for 
Windows, 
Beckton, 
Dickinson and 
Company, 
www.flowjo.com 
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Zebrafish 573 
Zebrafish were handled in accordance with protocols approved by the University of 574 
Massachusetts Medical School IACUC. Fish stocks were maintained in an animal 575 
facility at 28.5ºC on a 14-hour/10-hour Light/Dark cycle (Westerfield, 1995). The wild-576 
type strain used was AB. Published strains used in this study include gdf6a(lf) 577 
(gdf6as327) (Gosse and Baier, 2009), Tg(mitfa:eGFP) (Curran et al., 2009), 578 
Tg(crestin:eGFP) (Kaufman et al., 2016), Tg(crestin:mCherry) (Kaufman et al., 2016), 579 
mitfa(lf) (Lister et al., 1999), Tg(ubi:switch) (Mosimann et al., 2011), Tg(aox5:PALM-580 
eGFP) (Eom and Parichy, 2017). Construction of new strains generated are detailed 581 
below. 582 
 583 
DNA Constructs 584 
DNA constructs were built using Gateway cloning (Life Technologies). Sequences of 585 
gdf6a, dnBMPR (Pyati et al., 2005) and SMAD1-DVD (Nojima et al., 2010) were PCR-586 
amplified and cloned into pDONR221 (Life Technologies). Oligonucleotides used in 587 
cloning are described in Key Resources Section. Previously published entry clones 588 
used in this study were pENTRP4P1r-mitfa (Ceol et al., 2011), pDONR221-gdf6b 589 
(Venkatesan et al., 2018), pDONR221-CreERT2 (Mosimann et al., 2011). Previously 590 
published destination vectors used in this study are MiniCoopR (MCR) (Ceol et al., 591 
2011) and pcsDest2 (Villefranc et al., 2007). p3E-polyA, pME-eGFP, pDestTol2CG2, 592 
pDestTol2pA2, pCS2FA-transpoase were acquired from the Tol2Kit (Kwan et al., 2007). 593 
Using the entry clones and destination vectors described above, the following 594 
constructions were built using multisite or single site Gateway (Life Technologies): 595 
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MCR-mitfa:dnBMPR:pA, MCR-mitfa:eGFP:pA, MCR-mitfa:SMAD1-DVD:pA, 596 
pDestTol2CG2-mitfa:gdf6a:pA, pDestTol2pA2-mitfa:CreERT2:pA, pcsDest2-gdf6a, 597 
pcsDest2-gdf6b. All constructs were verified by restriction digest or sequencing. 598 
 599 
Construction of gdf6b(lf) 600 
To generate gdf6b(lf) mutants, we used TALEN genome editing. TALEN’s were 601 
designed targeting exon 1 of gdf6b (TAL1 sequence: GTCAGCATCACTGTTAT; TAL2 602 
sequence:  CCTTGATCGCCCTTCT). TALENs were assembled using the Golden Gate 603 
TALEN kit (Addgene) per the manufacturer’s instructions. TALEN plasmids were 604 
linearized and transcribed with mMESSAGE mMACHINE kit (Ambion). Zebrafish 605 
embryos were injected with 50 pg of mRNA of each TALEN arm. Injected embryos (F0) 606 
were matured to breeding age and outcrossed. Resulting offspring (F1) were genotyped 607 
by extraction genomic DNA from fin clips per standard protocol and PCR amplification 608 
with gdf6b primers. F1 offspring carrying mutations by genotyping were sequenced to 609 
identify mutations predicted to lead to loss of function of gdf6b. Following identification 610 
of candidate zebrafish by sequencing, zebrafish were bred to generate homozygous 611 
gdf6b(lf) mutations. Whole RNA was isolated from homozygous gdf6b(lf) embryos at 20 612 
HPF and qRT-PCR was used to determine effective depletion of gdf6b transcripts. 613 
Primers for genotyping and qRT-PCR are listed in the Key Reagents section. 614 
 615 
Construction of Tg(mitfa:gdf6a) 616 
To generate the Tg(mitfa:gdf6a) transgenic line, 25 pg of pDestTol2CG2-mitfa:gdf6a:pA 617 
was injected along with 25 pg of Tol2 transposase RNA, synthesized from pCS2FA-618 
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transposase, into single cell wild-type embryos (Kwan et al., 2007). Embryos were 619 
screened for incorporation of the transgene by expression of cmlc:eGFP in the heart at 620 
48 HPF. Animals with eGFP-positive hearts (F0) were outcrossed to wild-type animals 621 
to determine germline incorporation. 622 
 623 
Drug Treatments 624 
Drugs used in experiments were reconstituted at stock concentrations in solvent as 625 
follows: DMH1 (BMPi), 10mM in DMSO; Tamoxifen (4-OHT), 1mg/mL in ethanol; 626 
Epinephrine, 10mg/mL in embryo media. Embryos were dechorionated by incubating in 627 
Pronase (Roche) for 10 minutes with gentle shaking.  Dechorionated embryos were 628 
transferred to 6-well plates coated in 1.5% agarose in embryo media. Embryo media 629 
with appropriate drug concentration or vehicle control was added to each well. For BMPi 630 
and 4-OHT treatments, embryos were treated from 12 HPF (6ss) to 24 HPF (Prim-5). 631 
Embryos were incubated at 28.5ºC for the duration of the drug treatment. Following 632 
drug treatment, embryos were thoroughly washed in fresh embryo medium and returned 633 
to incubator in new embryo medium until analysis. 634 
 635 
Lineage Tracing 636 
To trace the lineage of embryonic pigment cells, Tg(ubi:switch) embryos were injected 637 
with 25 pg of pDestTol2pA2-mitfa:Cre-ERT2:pA and 25 pg of Tol2 transposase RNA at 638 
the single-cell stage. At 12 HPF, injected embryos were treated with BMPi and 4-OHT 639 
as described above. Following treatment, embryos were thoroughly washed and 640 
allowed to mature at 28.5ºC to 5 DPF. Embryos were treated with 1 mg/mL epinephrine 641 
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to contract melanosomes, anesthetized using 0.17mg/mL tricaine in embryo media, 642 
mounted in 1% low-melt agarose on a plastic dish, and submerged in embryo media for 643 
imaging. 644 
 645 
Mosaic Rescue 646 
MiniCoopR constructs MCR-mitfa:dnBMPR:pA, MCR-mitfa:SMAD1-DVD:pA, and MCR-647 
mitfa:eGFP:pA (control) were used. mitfa(lf) animals were injected with 25 pg of a single 648 
construct and 25 pg of Tol2 transposase RNA. Upon successful integration of the MCR 649 
constructs, the mitfa-minigene in the construct allowed development of melanocytes. 650 
Embryos were screened for incorporation of the transgene by rescue of melanocytes at 651 
5 DPF (Ceol et al., 2011). 652 
 653 
In Situ Hybridization 654 
RNA sense and anti-sense probes were synthesized from pcsDest2-gdf6a and 655 
pcsDest2-gdf6b constructs using DIG RNA Labeling Kit (Roche) per the manufacturer’s 656 
instruction. Wild-type embryos of the appropriate stage were fixed in 4% PFA at 4ºC for 657 
24 hours. Following fixation, embryos were dehydrated in methanol at stored at -20ºC. 658 
Whole mount in situ hybridization was performed as previously described (Reichert et 659 
al., 2013). Hybridized probes were detected using anti-digoxigenin (DIG) antibodies 660 
tagged with alkaline-phosphatase (AP) (Roche) using NBT/BCIP (Roche) solution per 661 
the manufacturer’s instructions. Stained embryos were mounted in 2.5% 662 
methylcellulose and imaged using a Leica M165FC microscope and Leica DFC400 663 
35 
camera. Specificity of the probes was verified using sense probes synthesized from the 664 
same construct. 665 
 666 
EdU Incorporation 667 
Embryos were dechorionated at the desired time and thoroughly washed in embryo 668 
media. Embryos were transferred to 1 mM EdU (Invitrogen), 10% DMSO in embryo 669 
media and incubated on ice for 1 hour, then incubated at 28.5ºC for 1 hour until the 670 
desired stage was reached. Embryos were washed thoroughly in fresh embryo media 671 
and fixed in 4% PFA for 2 hours. Following fixation, embryos were permeabilized by 672 
washing with 1% DMSO, 1% Triton X-100 in PBS for 1 hour. The EdU reaction mix was 673 
prepared per the manufacturer’s instructions. Embryos were then transferred to the 674 
reaction mix and incubated in the dark for 1 hour at room temperature. Following the 675 
reaction, embryos were washed in PBST and mounted for imaging. Cells were counted 676 
and data were analyzed using Microsoft Excel and GraphPad Prism 7. 677 
 678 
Immunofluorescence 679 
Embryos were fixed at the desired time or following drug treatment in 4% PFA for 24 680 
hours at 4ºC. Whole mount immunofluorescence was performed as previously 681 
described (Venkatesan et al., 2018). Primary antibodies used were pSMAD-1/5/8 (1:100 682 
dilution) (Cell Signal Technologies), HuC/D (1:100 dilution) (Sigma), mitfa (1:100 683 
dilution) (Venkatesan et al., 2018). AlexaFluor-488 (Invitrogen) and AlexaFluor-555 684 
(Invitrogen) conjugated secondary antibodies were used to detect primary antibody 685 
signaling. Nuclei were counterstained with DAPI. Following staining, animals were 686 
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dissected to remove yolk sack and flat mounted laterally on slides using VectaShield 687 
mounting medium. Fluorescent images were taken using a Leica DM5500 microscope 688 
with a Leica DFC365FX camera, and a Zeiss Axiovert 200 microscope outfitted with a 689 
Yokogawa spinning disk confocal scanner. Cells and structures were counted, and data 690 
was analyzed using Microsoft Excel and GraphPad Prism 7. 691 
 692 
Flow Cytometry & Fluorescence Activated Cell Sorting (FACS) 693 
Embryos were treated and matured to appropriate age as per drug treatment protocol 694 
described above. At a desired timepoint, embryos were washed in PBS and transferred 695 
to 500 µL of PBS + 5% FBS (FACS buffer). Embryos were mechanically dissociated in 696 
FACS buffer using a mortar and pestle. Dissociated embryos were washed with FACS 697 
buffer and filtered through a 40 µm mesh membrane. Samples were analyzed using a 698 
BD FACS Aria II flow cytometer and sorted directly into Trizol LS (Life Technologies) for 699 
RNA isolation. Flow cytometry data was analyzed using FlowJo software (Becton, 700 
Dickinson & Company) and GraphPad Prism 7. 701 
 702 
Quantitative Real-Time PCR (qRT-PCR) 703 
Oligos used for qRT-PCR primers are listed in Key Reagents section. RNA was isolated 704 
from FACS-sorted cells or whole embryos using Trizol reagent (Life Technologies) and 705 
purified using the RNeasy kit (Quiagen) per manufacturer’s protocol. cDNA was 706 
synthesized from purified RNA using the SuperScript III First Strand Synthesis kit 707 
(Thermo Fisher). Reaction mixes were assembled with SYBR Green RT-PCR master 708 
mix (Thermo Fisher), primers, and 25 ng cDNA, and analyzed using a StepOnePlus 709 
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Real Time PCR System (Applied Biosystems). All samples were normalized to β-actin, 710 
unless otherwise noted, and fold changes were calculated using the Ct method using 711 
Microsoft Excel and GraphPad Prism 7.  712 
 713 
Imaging and Quantification 714 
Zebrafish adults and embryos were treated with 1 mg/mL epinephrine to contract 715 
melanosomes prior to imaging unless otherwise noted. Fish were anesthetized in 0.17% 716 
Tricaine in embryo media and positioned in 2.5% methylcellulose in embryo media for 717 
imaging. Images of adult fish were captured with a Nikon D90 DSLR camera. Brightfield 718 
and incident light images of embryos were captured with Leica M165FC microscope 719 
and Leica DFC400 camera. Fluorescent images of embryos were captured with a Leica 720 
DM5500 upright microscope with a Leica DFC365FX camera, and a Zeiss Axiovert 200 721 
microscope outfitted with a Yokogawa spinning disk confocal scanner. Images were 722 
processed using ImageJ and Leica LAS X software. Cells were counted and analyses 723 
were performed using Microsoft Excel and GraphPad Prism 7. Statistical calculations 724 
were performed using GraphPad Prism 7 as described in each Figure legend. 725 
 726 
Statistical Analysis 727 
Statistical analyses were performing using GraphPad Prism 7 software package. 728 
Statistical significance of experiments was calculated using Student’s t-test, ratio-paired 729 
t-test, Fisher’s exact test with Bonferroni’s correction, 1-way ANOVA with Tukey’s 730 
multiple comparison test as described in each figure legend. Statistical significance was 731 
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denoted as follows: not significant (ns) P > 0.05, *P<0.05, **P<0.01, ***P<0.001 and 732 
****P<0.0001. 733 
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Figure 1. gdf6a loss or BMP inhibition causes the development of supernumerary 964 
melanocytes 965 
(A) Images of wild-type and gdf6a(lf) adult zebrafish, scale bar = 4 mm, inset scale bar 966 
= 1 mm. (B) Quantification of number of melanocytes (left) and scale pigmentation using 967 
melanin coverage (right), n = 3 scales per group. (C) Wild-type and gdf6a(lf) embryos 968 
imaged at 5 days post fertilization (DPF); vehicle- and BMPi-treated embryos imaged at 969 
5 DPF. Scale bar = 1 mm. Animals were treated with epinephrine prior to imaging. (D) 970 
Quantification of dorsal melanocytes per animal in 5 DPF wild-type, gdf6a(lf) mutant, 971 
vehicle-, and BMPi-treated embryos. n = 11, 9, 11, and 15 embryos, respectively, from 2 972 
independent experiments (N = 2). (E) Expression of melanocyte differentiation markers 973 
mc1r, tyr, and tyrp1b by qRT-PCR in wild-type, gdf6a(lf) mutant, vehicle-, and BMPi-974 
treated embryos. n = 5-6 replicates across 2 independent experiments (N = 2) for each 975 
group. Expression was normalized to β-actin. Error bars represent mean +/- SEM. P-976 
values were calculated using Student’s t-test in panel B and E, and one-way ANOVA 977 
with Tukey’s multiple comparisons test in panels D, * P<0.05, ** P<0.01, *** P<0.001, 978 
**** P<0.0001, n.s., not significant.  979 
 980 
Figure 1-figure supplement 1. gdf6 paralogs are necessary for normal embryonic 981 
development 982 
(A) Quantification of dorsal melanocytes in gdf6a(lf/+) heterozygotes, gdf6a(lf) 983 
homozygotes and wild-type embryos. (B) Quantification of whole-body melanocytes in 984 
vehicle- and BMPi-treated embryos. (C) Verification of gdf6a and gdf6b probe 985 
specificity. (D) RNA in situ hybridization for gdf6b at 12-, 18-, and 24-hours post-986 
45 
fertilization, scale bar = 500 µm. (E) Sequence of gdf6b(lf) mutant indicating deletion 987 
and frameshift in exon 1. (F) Decreased gdf6b expression in gdf6b(lf) embryos. (G) 988 
Quantification of dorsal melanocytes in gdf6b(lf) mutants compared to wild-type 989 
embryos. (H) Images of gdf6a(lf) and gdf6b(lf) mutant combinations. gdf6b(lf) animals 990 
have no morphologic defects compared to wild-type embryos at 5 DPF, while gdf6a(lf) 991 
animals show pigmentation and eye morphology defects. gdf6a(lf);gdf6b(lf) double 992 
mutants show significant morphologic defects associated with gdf6a(lf) as well as 993 
decreased body length, cardiac edema and hydrocephalus. Scale bar = 1 mm. (I) 994 
Survival of gdf6b(lf) embryos with gdf6a(lf) mutations. †, surviving embryos had various 995 
morphologic defects (cardiac edema, 63%; hydrocephalus, 21%; dysmorphic retina, 996 
96%; body length deficit, 96%; dorsalization, 71%). , surviving embryos had various 997 
morphologic defects (cardiac edema, 83%; hydrocephalus, 67%; dysmorphic retina, 998 
100%; body length deficit, 100%; dorsalization, 100%). Error bars represent mean +/- 999 
SEM. P-values were calculated using one-way ANOVA with Tukey’s multiple 1000 
comparison test for panel A and with Student’s t-test for panels B, F, and G. *** P < 1001 
0.001, **** P <0.0001, n.s., not significant. 1002 
 1003 
Figure 2. Inhibition of BMP signaling increases mitfa-positive neural crest cells 1004 
(A) Diagram of experiment. Tg(crestin:mCherry); Tg(mitfa:eGFP) embryos were treated 1005 
with BMPi from 12 to 24 HPF. At 24 HPF, embryos were dissociated and analyzed via 1006 
flow cytometry for GFP- and mCherry-positive cells, scale bar = 200 µm. (B) Gating 1007 
strategy based on non-transgenic wild-type control to identify crestin:mCherry-positive 1008 
cells and crestin:mCherry/mitfa:eGFP double-positive cells. Top, control vehicle-treated 1009 
46 
embryos. Bottom, BMPi-treated embryos. (C) Fold change in 1010 
crestin:mCherry/mitfa:eGFP double-positive cells per total crestin:mCherry-positive cells 1011 
in vehicle and BMPi-treated groups, N = 3 biological replicates of 80-100 stage-matched 1012 
embryos pooled for each condition. m:eGFP, mitfa:eGFP; c:mCherry, crestin:mCherry. 1013 
(D) anti-Mitfa immunofluorescence in Tg(crestin:eGFP) embryos treated with BMPi or 1014 
vehicle control and fixed at 24 hours, scaled bar = 10 µm. (E) Fold change in 1015 
Mitfa/crestin:eGFP double-positive cells per total crestin:eGFP-cells, n = 16 embryos 1016 
from 2 independent experiments (N = 2) for each condition. c:eGFP, crestin:eGFP. Error 1017 
bars represent mean +/- SEM; P-value was calculated using ratio-paired t-test in panel 1018 
C and Student’s t-test in panel E, * P < 0.05.  1019 
 1020 
Figure 2-figure supplement 1. Increased proliferation is not observed in neural 1021 
crest and pigment progenitor cell populations of BMPi-treated embryos 1022 
(A) Diagram of experiment. Embryos expressing either Tg(mitfa:eGFP) or 1023 
Tg(crestin:eGFP) were treated with BMP inhibitor from 12 to 24 HPF. Following 1024 
treatment, embryos were dissociated, fixed, and stained for DNA content using DAPI 1025 
and analyzed via flow cytometry. Scale bar = 200 µm. (B) Flow cytometry histograms 1026 
showing the percentage of cells in S/G2/M phases in crestin:eGFP-positive or 1027 
Tg(mitfa:eGFP-positive cell populations in BMPi-treated embryos compared to vehicle-1028 
treated embryos. (C) Fold change of crestin:eGFP-positive cells (top) and mitfa:eGFP-1029 
positive cells (bottom) in S/G2/M phases. n = 3 biological replicates of 80-100 stage-1030 
matched embryos pooled for each condition. (D) Diagram of experiment. Embryos 1031 
expressing either Tg(mitfa:eGFP) or Tg(crestin:eGFP) were treated with BMP inhibitor 1032 
47 
starting at 12 HPF. Embryos were concurrently treated with EdU from 12-14 HPF, 16-18 1033 
HPF, or 20-22 HPF. Following EdU treatment, embryos were fixed and assess for EdU 1034 
incorporation. (E) Example image of EdU incorporation in eGFP-positive cells in vehicle- 1035 
and BMPi-treated embryos. (F) Quantification of EdU incorporation in Tg(crestin:eGFP) 1036 
and Tg(mitfa:eGFP) embryos at different time points, n = 62-166 eGFP-positive cells 1037 
from 2 independent experiments (N = 2) for each condition and time point. Error bars 1038 
represent mean +/- SEM, P-values were calculated using ratio paired t-test for panel C 1039 
and Fisher’s exact test for panel F, n.s., not significant. 1040 
 1041 
Figure 3. gdf6a expression and BMP activity in pigment progenitor cells 1042 
(A) RNA in situ hybridization for gdf6a (top) and mitfa (bottom) at 12-, 18-, and 24-hours 1043 
post-fertilization. Arrowheads indicate expression domains in the region of the neural 1044 
crest of gdf6a and mitfa. Asterisk indicates known dorsal retinal expression of gdf6a. 1045 
Scale bar = 500 µm. (B) Expression of gdf6a and mitfa from neural crest cells isolated 1046 
from Tg(crestin:eGFP) embryos by FACS at 16 HPF and 22 HPF. Samples were 1047 
normalized to gdf6a expression. n = 5-6 replicates per conditions from 2 independent 1048 
experiments (N = 2).  (C) Images of GFP-positive cells from Tg(mitfa:eGFP) zebrafish 1049 
stained with α-pSMAD 1/5/8 antibody. Scale bar = 10 µm. (D) Quantification of 1050 
mitfa:eGFP-positive cells that are phospho-SMAD1/5/8-positive. The leading edge 1051 
encompassed the 5 most posterior mitfa-positive cells, whereas anterior cells 1052 
constituted any mitfa-positive cells anterior to the leading edge. n = 102 and 186 for 1053 
distal leading edge and anterior cells, respectively, from 3 independent experiments (N 1054 
48 
= 3). P-values were calculated using Fisher’s exact test for panels B and D, **** P < 1055 
0.0001. 1056 
 1057 
Figure 3-figure supplement 1. Treatment with the BMP inhibitor DMH1 reduces 1058 
phospho-SMAD1/5/8 staining in embryos 1059 
Top, vehicle-treated animals and, bottom, BMPi-treated animals showing lateral views 1060 
of developing muscle segments, identified by asterisks. Insets show individual nuclei. 1061 
Photomicrographs for pSMAD-1/5/8-stained embryos were taken at the same exposure 1062 
settings. 1063 
 1064 
Figure 4. BMP signaling within pigment progenitor cells can impact embryonic 1065 
melanocytes 1066 
(A) Tg(mitfa:gdf6a) and non-transgenic sibling control embryos (left), and quantification 1067 
of dorsal melanocytes per animal in each group (right). Animals were treated with 1068 
epinephrine prior to imaging at 5 DPF, n = 8 and 7 for control and Tg(mitfa:gdf6a) 1069 
groups, respectively, from 2 independent experiments (N = 2). Scale bar = 1 mm. (B) 1070 
Diagram of miniCoopR rescue experiment. Animals harboring a mitfa(lf) mutation were 1071 
injected at the single-cell stage with the miniCoopR vector containing a BMP gene. 1072 
Animals were evaluated at 5 DPF for the presence of melanocytes. If melanocytes were 1073 
present, that animal was scored as rescued, whereas animals lacking melanocytes 1074 
were scored as non-rescued. (C) Percentages of rescued and non-rescued animals 1075 
following injection of a miniCoopR-BMP vector, n = 361, 193 and 152 for control, 1076 
dnBMPR, and SMAD1-DVD groups, respectively, from 4 independent experiments (N = 1077 
49 
4). Error bars represent mean +/- SEM. P-values were calculated Student’s t-test for 1078 
panel A and with Fisher’s exact test with Bonferroni’s correction for panel C, * P <0.05, 1079 
** P <0.01, *** P <0.001 1080 
 1081 
Figure 5. gdf6a loss and BMP inhibition impact development of specific neural 1082 
crest derivatives 1083 
(A) Expression analyses of multiple neural crest and neural crest derivative lineage 1084 
markers. qRT-PCR was used to assess changes in markers of neural crest markers and 1085 
neural crest derivatives in gdf6a(lf) embryonic zebrafish (top) and BMPi-treated wild-1086 
type zebrafish (bottom) at 5 DPF; col2a1a, chondrocytes; mbpa, glial; pomca, adrenal 1087 
medullary cells; neurog1, neuronal cells; aox5, xanthophores; pnp4a, iridophores; n = 5-1088 
6 for each group from 2 independent experiments (N = 2). (B) Direct light (top) and 1089 
incident light (bottom) images of wild-type and gdf6a(lf) embryos at 5 DPF and 1090 
quantification of dorsal iridophores (right) per animal in each group. Animals were 1091 
treated with epinephrine prior to imaging at 5 DPF; n = 5 and 6 for wild-type and 1092 
gdf6a(lf) groups, respectively, from 2 independent experiments (N = 2); scale bar = 500 1093 
µm. (C) Direct light, top, and incident light, bottom, images of wild-type embryos treated 1094 
with vehicle or BMPi from 12 to 24 HPF and quantification of dorsal iridophores, right, 1095 
per animal in vehicle and BMPi treated groups. Animals treated with epinephrine prior to 1096 
imaging at 5 DPF, n = 6 and 6 for vehicle and BMPi groups, respectively, from 2 1097 
independent experiments (N = 2); scale bar = 1 mm. Error bars represent mean +/- 1098 
SEM, P-values calculated with Student’s t-test, * P < 0.05, ** P < 0.01, n.s., not 1099 
significant. 1100 
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 1101 
Figure 5-figure supplement 1. Neural crest cells and derivative populations show 1102 
variable response to BMP inhibition 1103 
(A) Expression analyses of neural crest markers foxd3 and sox10 by qRT-PCR in 1104 
gdf6a(lf) and BMPi-treated animals compared to controls, n = 4-6 replicates for each 1105 
condition from 2 independent experiments (N = 2). (B) Left, photomicrographs of wild-1106 
type/foxp3(lf) heterozygous and foxd3(lf) homozygous embryos under BMPi treatment 1107 
compared to controls, and, right, melanocyte quantification in these embryos, n = 23 1108 
and 9 control and foxd3(lf) embryos, respectively, from 2 independent experiments (N = 1109 
2). (C) Left, Hu C/D staining for dorsal root ganglion structures and, right, quantification 1110 
of dorsal root ganglia developing per segment, n = 5 per group. Scale bar = 50 µm. (D) 1111 
Left, photomicrographs of individual Hu C/D-stained DRG’s and, right, quantification in 1112 
the number of cells populating each individual DRG; n = 30 per group. Scale bar = 10 1113 
µm. (E) Left, Hu C/D staining for enteric neurons and, right, quantification of the number 1114 
of enteric neurons per field in developing gastrointestinal tract; n = 5 per group. Scale 1115 
bar = 50 µm. (F) Qualitative evaluation of xanthophore development using 1116 
Tg(aox5:PALM-eGFP) embryos treated with vehicle or BMPi showed no apparent 1117 
change in density or localization of xanthophores between vehicle- and BMPi-treated 1118 
embryos, supported by no change in aox5 expression as shown in Figure 5A. (G) Left, 1119 
Hu C/D staining of vehicle- and BMPi-treated Tg(mitfa:eGFP) embryos and, right, 1120 
quantification of mitfa:eGFP-positive, DRG-associated cells in control and BMPi-treated 1121 
groups, n = 8 and 12 DRG’s evaluated in vehicle- and BMPi-treated embryos, 1122 
51 
respectively, from 2 independent experiments (N = 2). Error bars represent mean +/- 1123 
SEM. P-values were calculated using Student’s t-test,  * P < 0.05, n.s., not significant. 1124 
 1125 
Figure 6. BMP inhibition impacts fate specification of mitfa-positive pigment 1126 
progenitor cells 1127 
(A) Diagram of lineage tracing experiment. Embryos containing Tg(ubi:switch) were 1128 
injected with a mitfa:Cre-ERT2 construct and treated with BMPi and tamoxifen (4-OHT) 1129 
from 12 to 24 HPF to block BMP signaling and allow Cre recombination. At 5 DPF, 1130 
animals were screened for successful recombination by presence of single mCherry-1131 
labeled pigment cells, and the identities of those cells were assessed using incident 1132 
light. Scale bar = 40 µm. (B) Quantification of mCherry-labeled cell fates at 5 DPF in 1133 
vehicle and BMPi-treated animals, n = 101 and 80 labeled cells for vehicle and BMPi 1134 
groups, respectively, from 5 independent experiments (N = 5); P-value calculated using 1135 
Fisher’s exact test, * P < 0.05. 1136 
 1137 
Figure 6-figure supplement 1. Quantification of iridophore and melanocyte 1138 
numbers from lineage tracing 1139 
Number of iridophores and melanocytes identified by lineage tracing under each 1140 
condition. P-value was calculated using Fisher’s exact test, P < 0.05. 1141 
 1142 
Figure 7. BMP signaling regulates expression of and acts through mitfa to impact 1143 
pigment cell fates 1144 
52 
(A) mitfa expression in sorted GFP-positive cells from Tg(crestin:eGFP) and 1145 
Tg(mitfa:eGFP) embryos treated with vehicle or BMPi from 12 to 24 HPF, n = 4-5 1146 
replicates for each condition from 2 independent experiments (N = 2). (B) anti-Mitfa 1147 
immunofluorescence, DAPI and merged images of Tg(crestin:eGFP) embryos treated 1148 
with vehicle control or BMPi in GFP-positive cells (top) and GFP-negative cells (bottom), 1149 
scale bar = 5 µm. (C) Quantification of anti-Mitfa fluorescence intensity of individual 1150 
nuclei in GFP-positive cells (top) and GFP-negative cells (bottom); n = 65 and 74 for 1151 
GFP-positive vehicle and BMPi groups, respectively; n = 35 and 30 for GFP-negative 1152 
vehicle and BMPi groups, respectively, from 3 independent experiments (N = 3). (D) 1153 
Incident light images of mitfa(lf) embryonic zebrafish treated with vehicle or BMPi from 1154 
12 to 24 HPF and imaged at 5 DPF, scale bar = 1 mm. (E) Quantification of dorsal 1155 
iridophores in mitfa(lf) embryonic zebrafish treated with vehicle or BMPi from 12 to 24 1156 
HPF, n = 7 and 9 for vehicle and BMPi groups, respectively, from 2 independent 1157 
experiments (N = 2). Error bars represent mean +/- SEM, P-value was calculated using 1158 
one-way ANOVA with Tukey’s multiple comparisons test in panel A and Student’s t-test 1159 
in panel C and E. * P <0.05, *** P <0.001, **** P<0.0001, n.s., not significant. 1160 
 1161 
Figure 7-figure supplement 1. Diagram of synteny between MITF and mitfa loci 1162 
and SMAD binding motifs at the mitfa locus. 1163 
(A) Diagram of orthologous genes flanking the MITF and mitfa loci in human and 1164 
zebrafish genomes, respectively. H. sapiens, Homo sapiens; D. rerio, Danio rerio. (B) 1165 
Diagram of mitfa locus, including promoter, intronic and exonic regions with identified 1166 
53 
SMAD binding motifs (SBM) and GC-rich SMAD binding motifs (GC-SBM). Scale bar = 1167 
200 bp. 1168 
 1169 
Supplementary file 1. Primers used for qRT-PCR and genotyping reactions. 1170 
(A) Primers used for qRT-PCR reactions. (B) Primers used for genotyping PCR 1171 
reactions and generation of Gateway compatible DNA fragments. 1172 
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